Disruptive Platform for advanced assessment and analysis of brain MRI studies powered by artificial intelligence (AI).

50 million individuals worldwide have a neurodegenerative disease, often resulting in dementia, a number expected to rise to 152 million by 2060. Moreover, 2.8 million people are affected by multiple sclerosis (MS). Early detection and treatment can help delay the progression of the disease. Our technology has the potential to revolutionise early diagnosis completely. Powered by AI, our MRI (brain) screening can detect a range of neurological diseases, including but not limited to Multiple Sclerosis (with emphasis on the progressive type differentiation and Double Inversion Recovery (DIR) sequence support), Alzheimer's (AD), Amyloid Related Imaging Abnormalities (ARIA), Atrophy, Aneurysm and more. At the heart of our solution are AI algorithms that generate reports with a comprehensive analysis of neuro-MRI studies. These reports include precise quantitative data on the volumetry of brain structures, allowing for tracking changes over time with particular attention to atrophy, vascular damage, and demyelinating changes. Through long-term insights, we assist in the early detection and monitoring of disease progression and the adjustment of personalised treatment plans for neurological disorders. Users will get the information on the fly in the automatically generated report accessible under its standard software PACS/RIS (integration with clinical/hospital software). The total estimated annual worldwide cost of dementia is over $1.3 trillion, and this figure is forecast to rise to $2.8 trillion by 2030. By supporting radiologists in fast and effective patient selection for treatment, we are potentially mitigating the high progression risk of various diseases. Moreover, our solution can be used during clinical studies with patients heading to new, effective drug development, having neurological diseases as the beginning of our mission.